# SureSeq

A Sysmex Group Company

## Innovative NGS myeloid malignancy solutions



### From sample to tertiary insights, bring clarity to your workflow

**At OGT, we develop pioneering hybridization technology that fits seamlessly into your workflows. Leveraging rational, expert-driven development, our SureSeq myeloid range offers:**

- **Enhanced detection of complex structural variants** – including those that are difficult for amplicon-based approaches
- **Better coverage uniformity** – even for hard-to-sequence GC rich regions of the genome
- **Clearer genetic profile of your sample** – with more unique fragments detected and reduced bias and error

# SureSeq

## Innovative NGS myeloid malignancy solutions

## Simplify the way you work with NGS

Traditional research approaches for myeloid malignancies can consign your laboratory to complex and time-consuming multi-stage workflows.

Our SureSeq™ myeloid malignancy research solutions are underpinned by a universal workflow compatible across all disease areas and product applications, unlocking the simplicity and efficiency you need. With our NGS myeloid solutions you also reap the benefits of reliably detecting *FLT3*-ITDs so you can free yourself from additional testing.

**Experience our fast, cost-effective myeloid NGS solutions and bring clarity to your workflow**

**1. Sample preparation**

**2. Genetic sequence**

**3. Variant detection**
with Interpret software

**4. Tertiary analysis**
with Intelliseq

## Empowering you with the latest developments

Be assured you're capturing the most important targets with SureSeq panels designed in collaboration with leading cancer experts

## Delivering exceptional uniformity

Confidently detect low-frequency SNVs and indels with our best-in-class design process, informed by our unique expertise, for exceptionally uniform coverage

## Robust detection of challenging biomarkers

Analyze difficult biomarkers, including *CEBPA*, *NPM1*, *FLT3*-ITDs (even up to 300 bp)[1] and *KMT2A*, with our hybridization-based approach and remove the need for supplementary approaches

## Seamless customization at the touch of a button

Access a library of over 1000 pre-optimized targets or request novel targets, so you only sequence the biomarkers that matter most to you

# SureSeq

## Innovative NGS myeloid malignancy solutions

OGT has you covered no matter your research or myeloid malignancy focus. With our broad range of NGS products we cover the full myeloid disease spectrum, so we have the solution for you, every time.

With SureSeq, you can alleviate the burden of running multiple assays in a single panel. Our expertly designed NGS solutions provide outstanding coverage uniformity so you can robustly detect:

- Low frequency SNVs and indels
- *FLT3*-ITDS, even for those as long as 300 bp
- *KMT2A*-PTDs of all sizes

**Visit ogt.com/myeloid-ngs or use the QR code to find out more.**

### SureSeq Core MPN Panel

Robustly detect key variants associated with MPN, with the flexibility to include *BCR-ABL* fusion gene detection.

**Product Code**
780001-24, 780001-96

**Reactions**
24, 96

**Panel Size**
1 Kb

**Number of Targets**
3 key clinically relevant genes (±*BCR-ABL* fusion)

### SureSeq Myeloid Plus Workflow

Accurately detect clinically relevant SNVs, indels and structural variants, even in challenging biomarkers, for a wide variety of myeloid malignancies.

**Product Code**
780002-24, 780002-96

**Reactions**
24, 96

**Panel Size**
132 Kb

**Number of Targets**
49 genes
(+4 sex chromosome genes)

### SureSeq Pan-Myeloid Panel

Obtain a comprehensive picture of the genetic make-up of every myeloid sample you run.

**Product Code**
780003-24, 780003-96

**Reactions**
24, 96

**Panel Size**
221 Kb

**Number of Targets**
70 genes
(+4 sex chromosome genes)

### SureSeq Myeloid Fusion Panel

Simultaneously detect all fusions of baited genes and enhance sample classification with novel/rare fusions.

**Product Code**
890001-24, 890001-96

**Reactions**
24, 96

**Panel Size**
61 Kb

**Number of Targets**
30+ fusions (+ partner gene-agnostic fusion detection for detection of novel fusion partners)

### SureSeq Myeloid MRD Panel

Comprehensively interrogate a wide range of targets with highly sensitive detection down to a possible 0.01% VAF.

**Product Code:**
780126-48, 770026-48

**Reactions:**
12, 12

**Panel Size**
11.2 Kb

**Number of Targets**
13 genes

### SureSeq myPanel Custom AML Panel

Create your ideal panel with our sophisticated bait design strategies and sequence only what's relevant for your AML research.

**Product Code**
Upon request

**Reactions**
Upon request

**Panel Size**
Upon request

**Number of Targets**
Contact our team to begin designing your panel

# SureSeq

## Innovative NGS myeloid malignancy solutions

## Unlock the full potential of NGS tertiary analysis

### Unparalleled genomic interpretation and report generation

With OGT unlock comprehensive end-to-end myeloid analyses, from sample to report. Our partnership with Intelliseq, a leading genome informatics company, brings you the innovation and expertise your research demands.

With our tertiary analysis solution, you can:

- Access ready-to-use report templates for myeloid malignancy panels
- Generate easily digestible insights with automated report generation
- Be assured of trustworthy results from up-to-date databases
- Customize your NGS analysis or report to suit your specific cancer research needs


Intelliseq

GeneSpect Report for Myeloid Cancer

Summary of the results

TIER I VARIANTS

| Gene | Mutation | AR / VAF | AMP/ASCO/CAP classification | FDA On-Label Therapy | Associated malignancy* |
|---|---|---|---|---|---|
| DNMT3A | NM_022552.5:c.1904G>A (p.Arg635Gln) | 0.0124 / 0.0123 | Tier IA | Not available | AML, CHIP, CCUS |
| SF3B1 | NM_012433.4:c.1866G>C (p.Glu622Asp) | 0.0124 / 0.0123 | Tier IA | Not available | AML, CLL, MDS |
| TET2 | NM_001127208.3:c.3407dupT (p.Glu1137fs) | 0.0124 / 0.0123 | Tier IA | Not available | AML, MDS, CMML, CHIP, CCUS |
| FLT3 | NM_004119.3:c.2503G>T (p.Asp835Tyr) | 0.0124 / 0.0123 | Tier IA | Gilteritinib, Quizartinib, Midostaurin | AML |

TIER II VARIANTS

| Gene | Mutation | AR / VAF | AMP/ASCO/CAP classification | FDA Off-Label Therapy | Associated malignancy* |
|---|---|---|---|---|---|
| NPM1 | NM_002520.7:c.58G>T (p.Gly20Cys) | 0.0124 / 0.0123 | Tier IIC | Not available | AML, MDS |

Risk category**: POOR/ADVERSE-RISK AML

Prognostic factors: *FLT3* TKD mutation and adverse-risk genetic lesion: *SF3B1*

FDA RECOMMENDATIONS

Option 1) Gilteritinib

Biomarker: *FLT3*

Gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (*FLT3*) mutation as detected by a n FDA-approved test.

Page 1/25 For Research Use Only. Not for use in diagnostic procedure. Generated: 03/20/2024

## Start your NGS journey with OGT today

**Contact one of our Myeloid NGS experts to discuss your project requirements. Visit ogt.com/myeloid-ngs or use the QR code to find out more.**

## Ordering information


**UK +44 (0) 1865 856800**

**US +1 914 467 5285**

**contact@ogt.com**

**ogt.com**


### References


1. Milner N *et al. Development of a target-capture NGS assay for use in molecular-based research of myeloid measurable residual disease (MRD).* Oxford Gene Technology. 2023. Available at: https://www.ogt.com/resources/ngs-resources-support/ngs-scientific-literature/


ogt

A Sysmex Group Company

**What binds us, makes us.**


**Oxford Gene Technology Inc., 520 White Plains Road, Suite 500, Tarrytown, NY 10591, USA**





990361_03/25 NA v3